Hyperkalemia Drugs Market Size Share Growth Opportunities and Forecast 2022

Hyperkalemia Drugs Market Size, Share, Industry, Forecast and outlook (2023-2030)

<h2>Global Hyperkalemia Drugs Market is segmented&nbsp;By Disease Type (Chronic hyperkalemia, Acute hyperkalemia),&nbsp;By Drug Type (Renin-angiotensin-aldosterone system inhibitors, ACE-inhibitors, Beta-blockers, Non-steroidal anti-inflammatory drugs, Others),&nbsp;By Distribution Channel (Retail pharmacies &amp; drugstores, Online Pharmacies),&nbsp;and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) &ndash; Share, Size, Outlook, and Opportunity Analysis, 2022-2029</h2>

&nbsp;

<h2>Market Overview</h2>

<blockquote>
The Global &quot;Hyperkalemia Drugs Market&quot;&nbsp;is expected to grow at a high <a href="https://www.datamintelligence.com/download-sample/hyperkalemia-drugs-market">CAGR of 20.7%</a> during the forecasting period (2022-2029).
</blockquote>

<h2>Trending Topics</h2>

<a href="https://www.datamintelligence.com/download-sample/antihyperlipidemic-drugs-market">Antihyperlipidemic Drugs Market</a>

<a href="https://www.datamintelligence.com/download-sample/dysthymia-drugs-market">Dysthymia Drugs Market</a>

<a href="https://www.datamintelligence.com/download-sample/schizophrenia-drugs-market">Schizophrenia Drugs Market</a>

<h2>&nbsp;</h2>

<h2>Table of Contents</h2>

<ol>
	<li>Methodology and Scope

	<ol>
		<li>Research Methodology</li>
		<li>Research Objective and Scope of the Report</li>
	</ol>
	</li>
	<li>Market Definition and Overview</li>
	<li>Executive Summary
	<ol>
		<li>Market Snippet by Disease Type</li>
		<li>Market Snippet by Drug Type</li>
		<li>Market Snippet by Distribution Channel</li>
		<li>Market Snippet by Region</li>
	</ol>
	</li>
	<li>&nbsp;Market Dynamics
	<ol>
		<li>Market Impacting Factors
		<ol>
			<li>Drivers
			<ol>
				<li>Increasing prevalence of hyperkalemia</li>
			</ol>
			</li>
			<li>Restraints
			<ol>
				<li>Associated drug Adverse Effects</li>
			</ol>
			</li>
			<li>Opportunity</li>
			<li>Impact Analysis</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Industry Analysis&nbsp;
	<ol>
		<li>Porter&#39;s Five Forces Analysis&nbsp;</li>
		<li>Regulatory Analysis</li>
		<li>Patent Analysis</li>
	</ol>
	</li>
	<li>Epidemiology Analysis&nbsp;</li>
	<li>Pipeline Analysis&nbsp;</li>
	<li>By Disease Type
	<ol>
		<li>&nbsp;Introduction&nbsp;
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Attractiveness Index, By Disease Type</li>
		</ol>
		</li>
		<li>Chronic hyperkalemia
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026</li>
		</ol>
		</li>
		<li>Acute hyperkalemia</li>
	</ol>
	</li>
	<li>By Drug Type
	<ol>
		<li>&nbsp;Introduction&nbsp;
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Attractiveness Index, By Drug Type</li>
		</ol>
		</li>
		<li>Renin-angiotensin-aldosterone system inhibitors
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026</li>
		</ol>
		</li>
		<li>&nbsp;&nbsp;&nbsp;ACE-inhibitors</li>
		<li>&nbsp;&nbsp;&nbsp;Beta blockers</li>
		<li>&nbsp;&nbsp;&nbsp;Non-steroidal anti-inflammatory drugs</li>
		<li>&nbsp;&nbsp;&nbsp;Others</li>
	</ol>
	</li>
	<li>By Distribution Channel
	<ol>
		<li>&nbsp;Introduction&nbsp;
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Attractiveness Index, By Distribution Channel</li>
		</ol>
		</li>
		<li>Retail pharmacies &amp; drugstores
		<ol>
			<li>Introduction</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), 2018-2026</li>
		</ol>
		</li>
		<li>Online Pharmacies</li>
	</ol>
	</li>
	<li>By Region
	<ol>
		<li>Introduction&nbsp;
		<ol>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Region</li>
			<li>Market Attractiveness Index, By Region</li>
		</ol>
		</li>
		<li>North America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>The U.S.</li>
				<li>Canada</li>
				<li>Mexico</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Europe
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Germany</li>
				<li>The U.K.</li>
				<li>France</li>
				<li>Italy</li>
				<li>Spain</li>
				<li>Rest of Europe</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>South America
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>Brazil</li>
				<li>Argentina</li>
				<li>Rest of South America</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Asia Pacific
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
			<ol>
				<li>China</li>
				<li>India</li>
				<li>Japan</li>
				<li>Australia</li>
				<li>Rest of Asia Pacific</li>
			</ol>
			</li>
		</ol>
		</li>
		<li>Middle East &amp; Africa
		<ol>
			<li>Introduction</li>
			<li>Key Region-Specific Dynamics</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Disease Type</li>
			<li>Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Type</li>
		</ol>
		</li>
	</ol>
	</li>
	<li>Competitive Landscape
	<ol>
		<li>Competitive Scenario</li>
		<li>Competitor&nbsp; Hyperkalemia Drugs Strategy Analysis</li>
		<li>Comparative Product Portfolio Analysis</li>
		<li>Market Positioning/Share Analysis</li>
		<li>Mergers and Acquisitions Analysis</li>
	</ol>
	</li>
	<li>Company Profiles
	<ol>
		<li>AstraZeneca
		<ol>
			<li>Company Overview</li>
			<li>Product Portfolio and Description</li>
			<li>Key Highlights</li>
			<li>Financial Overview</li>
		</ol>
		</li>
		<li>Relypsa, Inc.</li>
		<li>Vifor Pharma Management Ltd</li>
		<li>Ardelyx</li>
		<li>ZS Pharma, Inc</li>
		<li>Perrigo.</li>
		<li>Sanofi</li>
	</ol>
	</li>
	<li>Appendix</li>
	<li>About Us and Services</li>
	<li>Contact Us</li>
</ol>

<h2>&nbsp;</h2>

<h2 style="background:#eeeeee; border:1px solid #cccccc; padding:5px 10px">List of Tables &amp; Figures</h2>

LIST OF TABLES

TABLE 01. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, 2021, 2025 &amp; 2029 , BY DISEASE TYPE, ($MILLION)

TABLE 02. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE 2021, 2025 &amp; 2029, BY DISTRIBUTION CHANNEL, ($MILLION)

TABLE 03. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE 2021, 2025 &amp; 2029, BY DRUG TYPE, ($MILLION)

TABLE 04. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE 2021, 2025 &amp; 2029 , BY REGION, ($MILLION)

TABLE 05. GLOBAL HYPERKALEMIA DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY DISEASE TYPE ($MILLION)

TABLE 06. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

TABLE 07. GLOBAL HYPERKALEMIA DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY DISTRIBUTION CHANNEL ($MILLION)

TABLE 08. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY APPLICATION, 2018&ndash;2029 ($MILLION)

TABLE 09. GLOBAL HYPERKALEMIA DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY DRUG TYPE ($MILLION)

TABLE 10. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

TABLE 11. GLOBAL HYPERKALEMIA DRUGS MARKET SHARE 2021, 2025 &amp; 2029 (%), BY REGION ($MILLION)

TABLE 12. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY REGION, 2018&ndash;2029 ($MILLION)

TABLE 13. NORTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

TABLE 14. NORTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 15. NORTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

TABLE 16. NORTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 17. SOUTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

TABLE 18. SOUTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 19. SOUTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

TABLE 20. SOUTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 21. EUROPE HYPERKALEMIA DRUGS MARKET VALUE, BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

TABLE 22. EUROPE HYPERKALEMIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 23. EUROPE HYPERKALEMIA DRUGS MARKET VALUE, BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

TABLE 24. EUROPE HYPERKALEMIA DRUGS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 25. ASIA PACIFIC HYPERKALEMIA DRUGS MARKET VALUE, BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

TABLE 26. ASIA PACIFIC HYPERKALEMIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 27. ASIA PACIFIC HYPERKALEMIA DRUGS MARKET VALUE, BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

TABLE 28. ASIA PACIFIC HYPERKALEMIA DRUGS MARKET VALUE, BY COUNTRY, 2018&ndash;2029 ($MILLION)

TABLE 29. MIDDLE EAST &amp; AFRICA HYPERKALEMIA DRUGS MARKET VALUE, BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

TABLE 30. MIDDLE EAST &amp; AFRICA HYPERKALEMIA DRUGS MARKET VALUE, BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

TABLE 31. MIDDLE EAST &amp; AFRICA HYPERKALEMIA DRUGS MARKET VALUE, BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

TABLE 32. ASTRAZENECA: OVERVIEW

TABLE 33. ASTRAZENECA: DISEASE TYPE PORTFOLIO

TABLE 34. ASTRAZENECA: KEY DEVELOPMENTS

TABLE 35. RELYPSA, INC: OVERVIEW

TABLE 36. RELYPSA, INC: DISEASE TYPE PORTFOLIO

TABLE 37. RELYPSA, INC: KEY DEVELOPMENTS

TABLE 38. VIFOR PHARMA MANAGEMENT LTD: OVERVIEW

TABLE 39. VIFOR PHARMA MANAGEMENT LTD: DISEASE TYPE PORTFOLIO

TABLE 40. VIFOR PHARMA MANAGEMENT LTD: KEY DEVELOPMENTS

TABLE 41. ARDELYX.: OVERVIEW

TABLE 42. ARDELYX.: DISEASE TYPE PORTFOLIO

TABLE 43. ARDELYX.: KEY DEVELOPMENTS

TABLE 44. ZS PHARMA, INC: OVERVIEW

TABLE 45. ZS PHARMA, INC: DISEASE TYPE PORTFOLIO

TABLE 46. ZS PHARMA, INC: KEY DEVELOPMENTS

TABLE 47. PERRIGO: OVERVIEW

TABLE 48. PERRIGO: DISEASE TYPE PORTFOLIO

TABLE 49. PERRIGO: KEY DEVELOPMENTS

TABLE 50. SANOFI: OVERVIEW

TABLE 51. SANOFI.: DISEASE TYPE PORTFOLIO

TABLE 52. SANOFI.: KG: KEY DEVELOPMENTS

TABLE 53. COMPANY 8..: OVERVIEW

TABLE 54. COMPANY 8..: DISEASE TYPE PORTFOLIO

TABLE 55. COMPANY 8..: KEY DEVELOPMENTS

TABLE 56. COMPANY 9: OVERVIEW

TABLE 57. COMPANY 9: DISEASE TYPE PORTFOLIO

TABLE 58. COMPANY 9: KEY DEVELOPMENTS

TABLE 59. COMPANY 10: OVERVIEW

TABLE 60. COMPANY 10: DISEASE TYPE PORTFOLIO

TABLE 61. COMPANY 10: KEY DEVELOPMENTS

&nbsp;

LIST OF FIGURES

FIGURE 01. GLOBAL HYPERKALEMIA DRUGS MARKET SHARE, 2018 &amp; 2029 (%), BY DISEASE TYPE

FIGURE 02. GLOBAL HYPERKALEMIA DRUGS MARKET SHARE, 2018 &amp; 2029 (%), BY DISTRIBUTION CHANNEL

FIGURE 03. GLOBAL HYPERKALEMIA DRUGS MARKET SHARE, 2018 &amp; 2029 (%), BY DRUG TYPE

FIGURE 04. GLOBAL HYPERKALEMIA DRUGS MARKET SHARE, 2018 &amp; 2029 (%), BY REGION

FIGURE 05. GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, 2018 - 2029 AND YEAR ON YEAR GROWTH

FIGURE 06. GLOBAL HYPERKALEMIA DRUGS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY DISEASE TYPE

FIGURE 07 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY CHRONIC HYPERKALEMIA, 2018&ndash;2029 ($MILLION)

FIGURE 08 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY ACUTE HYPERKALEMIA, 2018&ndash;2029 ($MILLION)

FIGURE 10. GLOBAL HYPERKALEMIA DRUGS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY DISTRIBUTION CHANNEL

<a name="_GoBack"></a>FIGURE 11 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY RETAIL PHARMACIES &amp; DRUGSTORES PHARMACIES, 2018&ndash;2029 ($MILLION)

FIGURE 12 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY RETAIL PHARMACIES &amp; DRUGSTORESS, 2018&ndash;2029 ($MILLION)

FIGURE 13 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY ONLINE PHARMACIESS, 2018&ndash;2029 ($MILLION)

FIGURE 15 GLOBAL HYPERKALEMIA DRUGS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY DRUG TYPE

FIGURE 16 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE, BY RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM INHIBITORS, 2018&ndash;2029 ($MILLION)

FIGURE 17 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE , BY ACE-INHIBITORS, 2018&ndash;2029 ($MILLION)

FIGURE 18 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE , BY BETA BLOCKERS, 2018&ndash;2029 ($MILLION)

FIGURE 18 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE , BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS, 2018&ndash;2029 ($MILLION)

FIGURE 18 GLOBAL HYPERKALEMIA DRUGS MARKET VALUE , BY OTHERS, 2018&ndash;2029 ($MILLION)

FIGURE 19 GLOBAL HYPERKALEMIA DRUGS MARKET YEAR ON YEAR GROWTH 2018 TO 2029 (%), BY REGION

FIGURE 20 NORTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE, 2018&ndash;2029 ($MILLION)

FIGURE 21 NORTH AMERICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 22 NORTH AMERICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 23 NORTH AMERICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 24 NORTH AMERICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 25 SOUTH AMERICA HYPERKALEMIA DRUGS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 26 SOUTH AMERICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 27 SOUTH AMERICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 28 SOUTH AMERICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 29 SOUTH AMERICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 30 EUROPE HYPERKALEMIA DRUGS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 31 EUROPE HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 32 EUROPE HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 33 EUROPE HYPERKALEMIA DRUGS MARKET SHARE (%), BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 34 EUROPE HYPERKALEMIA DRUGS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 35 ASIA PACIFIC HYPERKALEMIA DRUGS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 36 ASIA PACIFIC HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 37 ASIA PACIFIC HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 38 ASIA PACIFIC HYPERKALEMIA DRUGS MARKET SHARE (%), BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 39 ASIA PACIFIC HYPERKALEMIA DRUGS MARKET SHARE (%), BY COUNTRIES, 2018&ndash;2029 ($MILLION)

FIGURE 40 MIDDLE EAST AND AFRICA HYPERKALEMIA DRUGS MARKET VALUE , 2018&ndash;2029 ($MILLION)

FIGURE 41 MIDDLE EAST AND AFRICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISEASE TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 42 MIDDLE EAST AND AFRICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2018&ndash;2029 ($MILLION)

FIGURE 43 MIDDLE EAST AND AFRICA HYPERKALEMIA DRUGS MARKET SHARE (%), BY DRUG TYPE, 2018&ndash;2029 ($MILLION)

FIGURE 44. ASTRAZENECA: FINANCIALS

FIGURE 45. RELYPSA, INC: FINANCIALS

FIGURE 46. VIFOR PHARMA MANAGEMENT LTD: FINANCIALS

FIGURE 47 COMPANY 9: FINANCIALS

FIGURE 48. ZS PHARMA, INC: FINANCIALS

FIGURE 49. PERRIGO: FINANCIALS

FIGURE 50. SANOFI: FINANCIALS

FIGURE 51. COMPANY 8.: FINANCIALS

FIGURE 52. ARDELYX..: FINANCIALS

FIGURE 53. PERRIGO: FINANCIALS